Trials / Active Not Recruiting
Active Not RecruitingNCT04905914
Study Of ATRN-119 In Patients With Advanced Solid Tumors
A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of Oral ATRN-119 In Patients With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 132 (estimated)
- Sponsor
- Aprea Therapeutics · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATRN-119 | ATRN-119 is a capsule formulation that will be supplied as 50 mg and 100 mg capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose. |
Timeline
- Start date
- 2023-01-09
- Primary completion
- 2028-02-01
- Completion
- 2028-02-01
- First posted
- 2021-05-28
- Last updated
- 2026-01-26
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04905914. Inclusion in this directory is not an endorsement.